TXNIP and gout: Recently, TXNIP, a known negative regulator of antioxidative protein thioredoxin [65], has emerged to be an attractive target in gouty arthritis [66], cervical inflammation [18], and CNS-related injury or diseases [15–18], implicating TXNIP as an important player in their pathogenesis.